RBA Wealth Management LLC Has $657,000 Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)


Share on StockTwits

RBA Wealth Management LLC trimmed its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 4.2% during the first quarter, Holdings Channel reports. The firm owned 10,164 shares of the biopharmaceutical company’s stock after selling 450 shares during the quarter. RBA Wealth Management LLC’s holdings in Gilead Sciences were worth $657,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Barrett Asset Management LLC raised its stake in Gilead Sciences by 333.0% during the 4th quarter. Barrett Asset Management LLC now owns 433 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 333 shares during the period. Tortoise Investment Management LLC raised its stake in Gilead Sciences by 81.6% during the 4th quarter. Tortoise Investment Management LLC now owns 445 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 200 shares during the period. TFO TDC LLC acquired a new position in Gilead Sciences during the 4th quarter worth approximately $26,000. Graves Light Private Wealth Management Inc. acquired a new position in Gilead Sciences during the 4th quarter worth approximately $27,000. Finally, Joseph P. Lucia & Associates LLC acquired a new position in Gilead Sciences during the 4th quarter worth approximately $29,000. 76.36% of the stock is currently owned by institutional investors.

In related news, EVP Brett A. Pletcher sold 1,486 shares of the business’s stock in a transaction that occurred on Thursday, March 11th. The shares were sold at an average price of $63.36, for a total value of $94,152.96. Following the completion of the transaction, the executive vice president now directly owns 29,166 shares in the company, valued at approximately $1,847,957.76. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Brett A. Pletcher sold 1,975 shares of the business’s stock in a transaction that occurred on Wednesday, February 10th. The stock was sold at an average price of $67.41, for a total transaction of $133,134.75. Following the completion of the transaction, the executive vice president now owns 28,832 shares of the company’s stock, valued at $1,943,565.12. The disclosure for this sale can be found here. 0.13% of the stock is owned by insiders.

A number of research firms recently weighed in on GILD. Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell dropped their price target on Gilead Sciences from $75.00 to $72.00 in a research note on Tuesday, December 22nd. Oppenheimer decreased their price objective on Gilead Sciences from $105.00 to $100.00 and set an “outperform” rating for the company in a report on Thursday, December 17th. Morgan Stanley boosted their price objective on Gilead Sciences from $83.00 to $87.00 and gave the stock an “overweight” rating in a report on Friday, February 5th. Credit Suisse Group boosted their price objective on Gilead Sciences from $65.00 to $66.00 and gave the stock a “neutral” rating in a report on Friday, February 5th. Finally, Smith Barney Citigroup decreased their price objective on Gilead Sciences from $75.00 to $72.00 in a report on Tuesday, December 22nd. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating and thirteen have issued a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $96.65.

Shares of NASDAQ:GILD traded up $0.58 on Friday, reaching $66.35. 178,906 shares of the company traded hands, compared to its average volume of 8,448,849. The business’s 50-day simple moving average is $64.31 and its 200 day simple moving average is $62.54. Gilead Sciences, Inc. has a 52 week low of $56.56 and a 52 week high of $85.79. The stock has a market capitalization of $83.54 billion, a P/E ratio of 67.80, a price-to-earnings-growth ratio of 0.67 and a beta of 0.51. The company has a current ratio of 3.25, a quick ratio of 3.15 and a debt-to-equity ratio of 1.65.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Thursday, February 4th. The biopharmaceutical company reported $2.19 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.15 by $0.04. Gilead Sciences had a net margin of 5.48% and a return on equity of 37.77%. The firm had revenue of $7.42 billion during the quarter, compared to analyst estimates of $7.11 billion. Sell-side analysts expect that Gilead Sciences, Inc. will post 7.06 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, March 30th. Investors of record on Monday, March 15th were issued a $0.71 dividend. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.68. This represents a $2.84 dividend on an annualized basis and a yield of 4.28%. The ex-dividend date was Friday, March 12th. Gilead Sciences’s payout ratio is presently 46.25%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases.

Recommended Story: Bear Market – How and Why They Occur

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.